Lipella Pharmaceuticals Inc. (LIPO) is a clinical-stage pharmaceutical company with no commercial revenue, a going-concern qualification, and a Nasdaq delisting effective June 20, 2025. Under a liquidation lens as of September 30, 2025, recovery to equity is marginally positive on paper but functionally near zero when wind-down costs and execution friction are considered. Total assets of $2.35M are dominated by cash and cash equivalents of $1.86M (100% recovery) and money-market equivalents of $1.73M within cash, alongside $0.22M in prepaid expenses (likely 30-50 cents on the dollar for insurance refunds, lower for clinical prepayments), a $0.26M right-of-use asset (zero recovery on liquidation under ASC 842), and $7,700 in net PP&E (furniture/fixtures, modest haircut). Intangible value — patents expiring 2034-2035 on LP-10 and LP-310 platform formulations — carries zero recovery weight under the liquidation lens. The 2022 NIH grant expired June 2025; grant receivable has been substantially collected per the filing. Total liabilities of $0.86M include $0.46M in accounts payable, $0.03M in accrued liabilities, $0.04M current operating lease liability, and $0.22M non-current operating lease liability. The lease renewal signed July 1, 2025 adds $311K in undiscounted future minimum payments ($264K present value) to the obligation stack — a material increase from the prior period when non-current lease liabilities were $0. Series B Preferred Stock (1,260 shares outstanding at 9/30/25) ranks senior to common equity on liquidation; stated value $100/share = $126K aggregate liquidation preference, which must be paid before any common distribution. Series B Warrants to purchase 72,000 Series B Preferred shares (at $100/share = $7.2M potential stated value) remain outstanding but are not yet a liability. Accumulated deficit stands at $19.2M against paid-in capital of $20.7M. Adjusted liquidation value to common equity: cash $1.86M at 100%, prepaid haircut ~$0.06M, PP&E $0.005M at 60%, less face-value liabilities of $0.86M, less Series B liquidation preference ~$0.13M, yields approximately $0.9-1.0M — consistent with MFFAIS CLV/LLV/OLV of $994K. Cash burn was $3.79M operating outflow YTD; management's own disclosure states cash will support operations only through end of 2025. No additional financing activity occurred in Q3 2025. The filing explicitly warns of potential dissolution and asset liquidation if capital is not raised. The lease renewal materially increases the contractual liability stack relative to the prior filing (where non-current lease was $0).
▼ Community Notes